Effects of inhibitory rTMS on bladder function in Parkinson's disease patients.
Identifieur interne : 002490 ( Ncbi/Merge ); précédent : 002489; suivant : 002491Effects of inhibitory rTMS on bladder function in Parkinson's disease patients.
Auteurs : Livia Brusa [Italie] ; Enrico Finazzi Agr ; Filomena Petta ; Francesco Sciobica ; Sara Torriero ; Emanuele Lo Gerfo ; Cesare Iani ; Paolo Stanzione ; Giacomo KochSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2009.
English descriptors
- KwdEn :
- Aged, Antiparkinson Agents (therapeutic use), Female, Humans, Levodopa (therapeutic use), Male, Middle Aged, Parkinson Disease (drug therapy), Parkinson Disease (epidemiology), Prostatic Neoplasms (diagnosis), Prostatic Neoplasms (epidemiology), Questionnaires, Severity of Illness Index, Time Factors, Transcranial Magnetic Stimulation (methods), Urinary Bladder, Overactive (epidemiology), Urinary Bladder, Overactive (physiopathology), Urinary Bladder, Overactive (therapy), Urodynamics.
- MESH :
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- diagnosis : Prostatic Neoplasms.
- drug therapy : Parkinson Disease.
- epidemiology : Parkinson Disease, Prostatic Neoplasms, Urinary Bladder, Overactive.
- methods : Transcranial Magnetic Stimulation.
- physiopathology : Urinary Bladder, Overactive.
- therapy : Urinary Bladder, Overactive.
- Aged, Female, Humans, Male, Middle Aged, Questionnaires, Severity of Illness Index, Time Factors, Urodynamics.
Abstract
Patients affected by Parkinson's disease (PD) may present with lower urinary tract (LUT) dysfunction characterized by involuntary detrusor overactivity. We evaluated possible impact of a 2-week course of low frequency 1 Hz repetitive transcranial magnetic stimulation (rTMS) on LUT behavior in eight advanced PD patients complaining of urinary disturbances. We tested the effects of rTMS measuring urodynamic examination and the International Prostate Symptoms Score (IPSS) questionnaire, used for evaluation of subjective LUTS. rTMS was able to improve temporarily LUT behavior in PD patients, increasing bladder capacity and the first sensation of filling phase. Moreover, a reduction of IPSS score was noticed, due to an improvement on filling phase symptoms. The beneficial effects assessed with the IPSS lasted for up to 2 weeks after the end of the stimulation. rTMS seems to be an effective, noninvasive alternative treatment for PD patients with urinary disturbances.
DOI: 10.1002/mds.22434
PubMed: 19133657
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001E74
- to stream PubMed, to step Curation: 001E74
- to stream PubMed, to step Checkpoint: 001E30
Links to Exploration step
pubmed:19133657Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effects of inhibitory rTMS on bladder function in Parkinson's disease patients.</title><author><name sortKey="Brusa, Livia" sort="Brusa, Livia" uniqKey="Brusa L" first="Livia" last="Brusa">Livia Brusa</name><affiliation wicri:level="3"><nlm:affiliation>UOC Neurologia, Ospedale S. Eugenio, Rome, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>UOC Neurologia, Ospedale S. Eugenio, Rome</wicri:regionArea><placeName><settlement type="city">Rome</settlement><region nuts="2">Latium</region></placeName></affiliation></author><author><name sortKey="Finazzi Agr, Enrico" sort="Finazzi Agr, Enrico" uniqKey="Finazzi Agr E" first="Enrico" last="Finazzi Agr">Enrico Finazzi Agr</name></author><author><name sortKey="Petta, Filomena" sort="Petta, Filomena" uniqKey="Petta F" first="Filomena" last="Petta">Filomena Petta</name></author><author><name sortKey="Sciobica, Francesco" sort="Sciobica, Francesco" uniqKey="Sciobica F" first="Francesco" last="Sciobica">Francesco Sciobica</name></author><author><name sortKey="Torriero, Sara" sort="Torriero, Sara" uniqKey="Torriero S" first="Sara" last="Torriero">Sara Torriero</name></author><author><name sortKey="Lo Gerfo, Emanuele" sort="Lo Gerfo, Emanuele" uniqKey="Lo Gerfo E" first="Emanuele" last="Lo Gerfo">Emanuele Lo Gerfo</name></author><author><name sortKey="Iani, Cesare" sort="Iani, Cesare" uniqKey="Iani C" first="Cesare" last="Iani">Cesare Iani</name></author><author><name sortKey="Stanzione, Paolo" sort="Stanzione, Paolo" uniqKey="Stanzione P" first="Paolo" last="Stanzione">Paolo Stanzione</name></author><author><name sortKey="Koch, Giacomo" sort="Koch, Giacomo" uniqKey="Koch G" first="Giacomo" last="Koch">Giacomo Koch</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="doi">10.1002/mds.22434</idno><idno type="RBID">pubmed:19133657</idno><idno type="pmid">19133657</idno><idno type="wicri:Area/PubMed/Corpus">001E74</idno><idno type="wicri:Area/PubMed/Curation">001E74</idno><idno type="wicri:Area/PubMed/Checkpoint">001E30</idno><idno type="wicri:Area/Ncbi/Merge">002490</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Effects of inhibitory rTMS on bladder function in Parkinson's disease patients.</title><author><name sortKey="Brusa, Livia" sort="Brusa, Livia" uniqKey="Brusa L" first="Livia" last="Brusa">Livia Brusa</name><affiliation wicri:level="3"><nlm:affiliation>UOC Neurologia, Ospedale S. Eugenio, Rome, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>UOC Neurologia, Ospedale S. Eugenio, Rome</wicri:regionArea><placeName><settlement type="city">Rome</settlement><region nuts="2">Latium</region></placeName></affiliation></author><author><name sortKey="Finazzi Agr, Enrico" sort="Finazzi Agr, Enrico" uniqKey="Finazzi Agr E" first="Enrico" last="Finazzi Agr">Enrico Finazzi Agr</name></author><author><name sortKey="Petta, Filomena" sort="Petta, Filomena" uniqKey="Petta F" first="Filomena" last="Petta">Filomena Petta</name></author><author><name sortKey="Sciobica, Francesco" sort="Sciobica, Francesco" uniqKey="Sciobica F" first="Francesco" last="Sciobica">Francesco Sciobica</name></author><author><name sortKey="Torriero, Sara" sort="Torriero, Sara" uniqKey="Torriero S" first="Sara" last="Torriero">Sara Torriero</name></author><author><name sortKey="Lo Gerfo, Emanuele" sort="Lo Gerfo, Emanuele" uniqKey="Lo Gerfo E" first="Emanuele" last="Lo Gerfo">Emanuele Lo Gerfo</name></author><author><name sortKey="Iani, Cesare" sort="Iani, Cesare" uniqKey="Iani C" first="Cesare" last="Iani">Cesare Iani</name></author><author><name sortKey="Stanzione, Paolo" sort="Stanzione, Paolo" uniqKey="Stanzione P" first="Paolo" last="Stanzione">Paolo Stanzione</name></author><author><name sortKey="Koch, Giacomo" sort="Koch, Giacomo" uniqKey="Koch G" first="Giacomo" last="Koch">Giacomo Koch</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antiparkinson Agents (therapeutic use)</term><term>Female</term><term>Humans</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (epidemiology)</term><term>Prostatic Neoplasms (diagnosis)</term><term>Prostatic Neoplasms (epidemiology)</term><term>Questionnaires</term><term>Severity of Illness Index</term><term>Time Factors</term><term>Transcranial Magnetic Stimulation (methods)</term><term>Urinary Bladder, Overactive (epidemiology)</term><term>Urinary Bladder, Overactive (physiopathology)</term><term>Urinary Bladder, Overactive (therapy)</term><term>Urodynamics</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Prostatic Neoplasms</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Parkinson Disease</term><term>Prostatic Neoplasms</term><term>Urinary Bladder, Overactive</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Transcranial Magnetic Stimulation</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Urinary Bladder, Overactive</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Urinary Bladder, Overactive</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Questionnaires</term><term>Severity of Illness Index</term><term>Time Factors</term><term>Urodynamics</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Patients affected by Parkinson's disease (PD) may present with lower urinary tract (LUT) dysfunction characterized by involuntary detrusor overactivity. We evaluated possible impact of a 2-week course of low frequency 1 Hz repetitive transcranial magnetic stimulation (rTMS) on LUT behavior in eight advanced PD patients complaining of urinary disturbances. We tested the effects of rTMS measuring urodynamic examination and the International Prostate Symptoms Score (IPSS) questionnaire, used for evaluation of subjective LUTS. rTMS was able to improve temporarily LUT behavior in PD patients, increasing bladder capacity and the first sensation of filling phase. Moreover, a reduction of IPSS score was noticed, due to an improvement on filling phase symptoms. The beneficial effects assessed with the IPSS lasted for up to 2 weeks after the end of the stimulation. rTMS seems to be an effective, noninvasive alternative treatment for PD patients with urinary disturbances.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">19133657</PMID><DateCreated><Year>2009</Year><Month>03</Month><Day>03</Day></DateCreated><DateCompleted><Year>2009</Year><Month>07</Month><Day>27</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>3</Issue><PubDate><Year>2009</Year><Month>Feb</Month><Day>15</Day></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>Effects of inhibitory rTMS on bladder function in Parkinson's disease patients.</ArticleTitle><Pagination><MedlinePgn>445-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.22434</ELocationID><Abstract><AbstractText>Patients affected by Parkinson's disease (PD) may present with lower urinary tract (LUT) dysfunction characterized by involuntary detrusor overactivity. We evaluated possible impact of a 2-week course of low frequency 1 Hz repetitive transcranial magnetic stimulation (rTMS) on LUT behavior in eight advanced PD patients complaining of urinary disturbances. We tested the effects of rTMS measuring urodynamic examination and the International Prostate Symptoms Score (IPSS) questionnaire, used for evaluation of subjective LUTS. rTMS was able to improve temporarily LUT behavior in PD patients, increasing bladder capacity and the first sensation of filling phase. Moreover, a reduction of IPSS score was noticed, due to an improvement on filling phase symptoms. The beneficial effects assessed with the IPSS lasted for up to 2 weeks after the end of the stimulation. rTMS seems to be an effective, noninvasive alternative treatment for PD patients with urinary disturbances.</AbstractText><CopyrightInformation>(c) 2009 Movement Disorder Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brusa</LastName><ForeName>Livia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>UOC Neurologia, Ospedale S. Eugenio, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Finazzi Agrò</LastName><ForeName>Enrico</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Petta</LastName><ForeName>Filomena</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Sciobica</LastName><ForeName>Francesco</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Torriero</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Lo Gerfo</LastName><ForeName>Emanuele</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Iani</LastName><ForeName>Cesare</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Stanzione</LastName><ForeName>Paolo</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Koch</LastName><ForeName>Giacomo</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D010300">Parkinson Disease</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000453">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011471">Prostatic Neoplasms</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011795">Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D012720">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D050781">Transcranial Magnetic Stimulation</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y" UI="D053201">Urinary Bladder, Overactive</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000453">epidemiology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName><QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D014563">Urodynamics</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>1</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>1</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>7</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1002/mds.22434</ArticleId><ArticleId IdType="pubmed">19133657</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Italie</li></country><region><li>Latium</li></region><settlement><li>Rome</li></settlement></list><tree><noCountry><name sortKey="Finazzi Agr, Enrico" sort="Finazzi Agr, Enrico" uniqKey="Finazzi Agr E" first="Enrico" last="Finazzi Agr">Enrico Finazzi Agr</name><name sortKey="Iani, Cesare" sort="Iani, Cesare" uniqKey="Iani C" first="Cesare" last="Iani">Cesare Iani</name><name sortKey="Koch, Giacomo" sort="Koch, Giacomo" uniqKey="Koch G" first="Giacomo" last="Koch">Giacomo Koch</name><name sortKey="Lo Gerfo, Emanuele" sort="Lo Gerfo, Emanuele" uniqKey="Lo Gerfo E" first="Emanuele" last="Lo Gerfo">Emanuele Lo Gerfo</name><name sortKey="Petta, Filomena" sort="Petta, Filomena" uniqKey="Petta F" first="Filomena" last="Petta">Filomena Petta</name><name sortKey="Sciobica, Francesco" sort="Sciobica, Francesco" uniqKey="Sciobica F" first="Francesco" last="Sciobica">Francesco Sciobica</name><name sortKey="Stanzione, Paolo" sort="Stanzione, Paolo" uniqKey="Stanzione P" first="Paolo" last="Stanzione">Paolo Stanzione</name><name sortKey="Torriero, Sara" sort="Torriero, Sara" uniqKey="Torriero S" first="Sara" last="Torriero">Sara Torriero</name></noCountry><country name="Italie"><region name="Latium"><name sortKey="Brusa, Livia" sort="Brusa, Livia" uniqKey="Brusa L" first="Livia" last="Brusa">Livia Brusa</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002490 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 002490 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:19133657
|texte= Effects of inhibitory rTMS on bladder function in Parkinson's disease patients.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:19133657" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |